Vapotherm (VAPO) Downgraded by Zacks Investment Research to “Sell”

Vapotherm (NYSE:VAPO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute breathing disorders. The Company provides flow vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “

Separately, Canaccord Genuity boosted their target price on Vapotherm from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Vapotherm currently has a consensus rating of “Buy” and a consensus price target of $26.50.

Shares of NYSE:VAPO traded up $0.38 on Friday, hitting $17.68. The company’s stock had a trading volume of 10,674 shares, compared to its average volume of 43,507. Vapotherm has a 1 year low of $14.70 and a 1 year high of $22.29. The stock has a market cap of $295.82 million and a P/E ratio of -1.28. The company has a quick ratio of 4.84, a current ratio of 5.82 and a debt-to-equity ratio of 0.61.

Vapotherm (NYSE:VAPO) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.40) by $0.12. The business had revenue of $11.69 million during the quarter, compared to analysts’ expectations of $11.00 million. On average, equities research analysts expect that Vapotherm will post -2.86 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in VAPO. American International Group Inc. acquired a new position in shares of Vapotherm in the fourth quarter worth $61,000. New York State Common Retirement Fund acquired a new position in shares of Vapotherm in the fourth quarter worth $118,000. Deutsche Bank AG acquired a new position in shares of Vapotherm in the fourth quarter worth $121,000. Barclays PLC acquired a new position in shares of Vapotherm in the fourth quarter worth $142,000. Finally, Arnhold LLC acquired a new position in shares of Vapotherm in the fourth quarter worth $227,000. 47.51% of the stock is currently owned by institutional investors.

About Vapotherm

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Get a free copy of the Zacks research report on Vapotherm (VAPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.